(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.43%.
Palvella Therapeutics's earnings in 2025 is -$35,066,000.On average, 17 Wall Street analysts forecast PVLA's earnings for 2025 to be -$42,274,024, with the lowest PVLA earnings forecast at -$42,223,127, and the highest PVLA earnings forecast at -$35,544,979. On average, 17 Wall Street analysts forecast PVLA's earnings for 2026 to be -$46,792,012, with the lowest PVLA earnings forecast at -$57,070,820, and the highest PVLA earnings forecast at -$36,539,245.
In 2027, PVLA is forecast to generate -$70,661,478 in earnings, with the lowest earnings forecast at -$116,693,588 and the highest earnings forecast at -$39,894,890.